Strongbridge Drug Patent Portfolio
Strongbridge owns 1 orange book drug protected by 9 US patents Given below is the list of Strongbridge's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11020393 | Methods of treating disease with levoketoconazole | 02 Mar, 2040 | Active |
| US11278547 | Methods of treating disease with levoketoconazole | 02 Mar, 2040 | Active |
| US11903940 | Methods of treating disease with levoketoconazole | 02 Mar, 2040 | Active |
| US12377096 | Methods Of Treating Disease With Levoketoconazole | 02 Mar, 2040 | Active |
| US9918984 | Methods and compositions for treating diabetes, metabolic syndrome and other conditions | 03 May, 2028 | Active |
| US10098877 | Methods and compositions for treating diabetes, metabolic syndrome and other conditions | 10 Jan, 2026 | Expired |
| US10517868 | Methods and compositions for treating diabetes, metabolic syndrome and other conditions | 10 Jan, 2026 | Expired |
| US10835530 | Methods and compositions for treating diabetes, metabolic syndrome and other conditions | 10 Jan, 2026 | Expired |
| US11478471 | Methods and compositions for treating diabetes, metabolic syndrome and other conditions | 10 Jan, 2026 | Expired |
Latest Legal Activities on Strongbridge's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Strongbridge.
| Activity | Date | Patent Number |
|---|---|---|
| ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 12 Sep, 2025 | US11278547 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 10 Sep, 2025 | US9918984 |
| Recordation of Patent Grant Mailed | 12 Aug, 2025 | US12377096 |
| Mail Patent eGrant Notification | 05 Aug, 2025 | US12377096 |
| Recordation of Patent eGrant | 05 Aug, 2025 | US12377096 |
| Patent Issue Date Used in PTA Calculation | 05 Aug, 2025 | US12377096 |
| Patent eGrant Notification | 05 Aug, 2025 | US12377096 |
| Email Notification | 05 Aug, 2025 | US12377096 |
| Email Notification | 24 Jul, 2025 | US12377096 |
| Issue Notification Mailed | 23 Jul, 2025 | US12377096 |
| Dispatch to FDC | 08 Jul, 2025 | US12377096 |
| Application Is Considered Ready for Issue | 08 Jul, 2025 | US12377096 |
| Mailing Corrected Notice of Allowability | 01 Jul, 2025 | US12377096 |
| Email Notification | 01 Jul, 2025 | US12377096 |
| Issue Fee Payment Received | 01 Jul, 2025 | US12377096 |
Strongbridge's Family Patents
Strongbridge Drug List
Given below is the complete list of Strongbridge's drugs and the patents protecting them.
1. Recorlev
Recorlev is protected by 9 patents, out of which 4 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11020393 | Methods of treating disease with levoketoconazole |
02 Mar, 2040
(13 years from now)
| Active |
| US11278547 | Methods of treating disease with levoketoconazole |
02 Mar, 2040
(13 years from now)
| Active |
| US11903940 | Methods of treating disease with levoketoconazole |
02 Mar, 2040
(13 years from now)
| Active |
| US12377096 | Methods Of Treating Disease With Levoketoconazole |
02 Mar, 2040
(13 years from now)
| Active |
| US9918984 | Methods and compositions for treating diabetes, metabolic syndrome and other conditions |
03 May, 2028
(2 years from now)
| Active |
| US10098877 | Methods and compositions for treating diabetes, metabolic syndrome and other conditions |
10 Jan, 2026
(2 months ago)
| Expired |
| US10517868 | Methods and compositions for treating diabetes, metabolic syndrome and other conditions |
10 Jan, 2026
(2 months ago)
| Expired |
| US10835530 | Methods and compositions for treating diabetes, metabolic syndrome and other conditions |
10 Jan, 2026
(2 months ago)
| Expired |
| US11478471 | Methods and compositions for treating diabetes, metabolic syndrome and other conditions |
10 Jan, 2026
(2 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Recorlev's drug page